IP Library Granted Patent US 6,906,107
Granted Patent B2
US 6,906,107 · App. 10/468,138 · Granted Jun 14, 2005

Use of cyclohexenone derivatives for the manufacture of a medicament in the treatment of dysuria

Assignee: Meiji Dairies Corporation
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,906,107
App. No.
10/468,138
Granted
Jun 14, 2005
Kind
B2
Abstract

A preventive and/or therapeutic agent for dysuria, which comprises as an effective ingredient a cyclohexenone long-chain alcoholic derivative represented by the following formula (1): [wherein, R 1 , R 2 and R 3 each independently represents a hydrogen atom or a methyl group and X represents a linear or branched C 10-28 alkylene or alkenylene group]. This compound alleviates dysuria due to hypofunction of the urinary bladder so that they are useful as a preventive and/or therapeutic agent for dysuria

Claims (8)

1. A method of preventing or treating dysuria due to hypofunction of a functioning urinary bladder in a subject in need of such prevention or treatment, which comprises administering an effective amount of a cyclohexenone long-chain alcoholic derivative, represented by the following formula (I):

wherein R 1 , R 2 and R 3 each independently represents a hydrogen atom or a methyl group and X represents a linear or branched C 10-28 alkylene or alkenylene group or a salt solvate or hydrate thereof.

2. A method of treating dysuria in a patient in need of treatment which comprises administering an effective amount of the compound of formula (1) as defined in claim 1 to the patient.

3. The method of claim 2 , wherein said patient is a human being.

4. The method of claim 3 , wherein said administering is through an oral route.

5. The method of claim 3 wherein said administering is through a parenteral route.

6. The method of claim 3 wherein said effective amount is 0.01 to 1,000 mg/day for an adult human.

7. The method of claim 1 , wherein said compound of formula (1) is 3-(15-Hydroxypentadecyl)-2,4,4-trimethyl-2-cyclohexen-1-one.

Assignments (3)
ASSIGNMENT (PARTIAL RIGHTS) Recorded Jul 9, 2012
From: MEIJI CO., LTD.
To: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE; UNIVERSITE DE STRASBOURG
Reel/Frame 028510/0193 →
CHANGE OF NAME Recorded Aug 9, 2011
From: MEIJI DAIRIES CORPORATION
To: MEIJI CO., LTD.
Reel/Frame 026724/0012 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 2, 2004
From: MIYAGAWA, MASAO; WATANABE, TAKESHI; SAITO, MOTOAKI; LUU, BANG; YAMADA, MASASHI; SUZUKI, HIROTO
To: MEIJI DAIRIES CORPORATION
Reel/Frame 014942/0971 →
Priority Claims (1)
JP 2001-041587 · Feb 19, 2001 · national
Continuity (1)
Related Publication 20040132829A1 · Jul 8, 2004